Ravi Keerthi

Ravi Keerthi

Active Director Director DIN 08377428
DIN 08377428 First appointment Feb 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2019
Shareholding value •••• Premium profile

About Ravi Keerthi

Data last updated:

Ravi Keerthi is a Director at Synryn Pharma Private Limited (since 2019). The company operates in Pharma. Synryn Pharma Private Limited reported revenue of ₹2.91 Cr (FY 2025).

DIN 08377428
Primary Designation Director
Industry Pharma
First Appointment 25 Feb 2019
Oldest Company Age 8 yrs
Largest company Synryn Pharma Private Limited · ₹2.91 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Synryn Pharma Private Limited U73200TG2018PTC126873
Director25 Feb 20192018₹2.91 Cr (FY 2025)Active

Board colleagues of Ravi Keerthi

NameDINCompanyDesignation
Venkat Reddy Sappidi06741903Synryn Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Synryn Pharma Private Limited
Premium access

Shareholding and investment profile for Ravi Keerthi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Keerthi

Ravi Keerthi currently holds 1 directorship: Synryn Pharma Private Limited (Director, since 25 Feb 2019, revenue ₹2.91 Cr (FY 2025)).

Ravi Keerthi was first appointed on 25 Feb 2019 as Director at Synryn Pharma Private Limited.

The current boards of Ravi Keerthi's companies include Venkat Reddy Sappidi (Synryn Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available